Phreesia, Inc. (NYSE:PHR) Shares Purchased by Algert Global LLC

Algert Global LLC raised its holdings in shares of Phreesia, Inc. (NYSE:PHR - Free Report) by 190.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 77,833 shares of the company's stock after buying an additional 51,006 shares during the period. Algert Global LLC owned about 0.13% of Phreesia worth $1,958,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of PHR. Greenhouse Funds LLLP boosted its position in Phreesia by 27.9% in the 4th quarter. Greenhouse Funds LLLP now owns 2,873,892 shares of the company's stock valued at $72,307,000 after buying an additional 626,579 shares during the period. Park West Asset Management LLC purchased a new stake in shares of Phreesia in the fourth quarter valued at approximately $10,657,000. ExodusPoint Capital Management LP grew its stake in Phreesia by 448.6% in the fourth quarter. ExodusPoint Capital Management LP now owns 174,971 shares of the company's stock worth $4,402,000 after purchasing an additional 143,077 shares in the last quarter. ArrowMark Colorado Holdings LLC grew its stake in Phreesia by 41.2% in the fourth quarter. ArrowMark Colorado Holdings LLC now owns 484,617 shares of the company's stock worth $12,193,000 after purchasing an additional 141,411 shares in the last quarter. Finally, Barclays PLC increased its holdings in Phreesia by 120.4% during the 4th quarter. Barclays PLC now owns 209,209 shares of the company's stock worth $5,264,000 after purchasing an additional 114,280 shares during the period. Institutional investors own 92.10% of the company's stock.

Phreesia Stock Up 1.1%

Shares of PHR stock traded up $0.29 during trading hours on Wednesday, reaching $26.39. 127,806 shares of the company's stock were exchanged, compared to its average volume of 434,279. Phreesia, Inc. has a fifty-two week low of $17.07 and a fifty-two week high of $30.53. The stock's 50 day moving average is $25.12 and its 200-day moving average is $24.83. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.04. The company has a market cap of $1.55 billion, a price-to-earnings ratio of -17.95 and a beta of 0.74.

Insider Buying and Selling

In other Phreesia news, SVP David Linetsky sold 4,499 shares of the stock in a transaction dated Wednesday, April 16th. The stock was sold at an average price of $23.73, for a total value of $106,761.27. Following the completion of the sale, the senior vice president now directly owns 217,239 shares in the company, valued at approximately $5,155,081.47. This trade represents a 2.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Balaji Gandhi sold 28,759 shares of the business's stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $30.00, for a total value of $862,770.00. Following the sale, the chief financial officer now owns 116,174 shares in the company, valued at $3,485,220. The trade was a 19.84% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 111,640 shares of company stock worth $3,094,167 in the last ninety days. 5.80% of the stock is owned by insiders.

Analyst Ratings Changes

PHR has been the subject of several research reports. Canaccord Genuity Group upped their target price on Phreesia from $34.00 to $35.00 and gave the stock a "buy" rating in a report on Thursday, March 13th. DA Davidson lowered their price objective on shares of Phreesia from $36.00 to $34.00 and set a "buy" rating for the company in a research note on Monday, April 14th. Piper Sandler reiterated an "overweight" rating and set a $33.00 target price (up from $31.00) on shares of Phreesia in a report on Wednesday, January 29th. KeyCorp reduced their price target on shares of Phreesia from $30.00 to $28.00 and set an "overweight" rating for the company in a report on Wednesday, April 16th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $29.00 price objective on shares of Phreesia in a research note on Thursday, March 13th. Twelve investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $31.33.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.